3 Dividend Stocks From a Value Pro

In a rocky market, dividend stocks with generous yields and solid growth prospects may be just what your portfolio needs—if you can find them.

Barrons • Sep 4, 2026

Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns.

24/7 Wall Street • Aug 31, 2026

Jim Cramer Calls This Mining Stock an Inflation Hedge “Just as Good as Crypto”

On a recent edition of CNBC's Mad Money Lightning Round, Jim Cramer fielded questions from viewers. Two of Cramer's clearest calls were to buy Vale (NYSE:VALE | VALE Price Prediction) as an inflation hedge comparable to cryptocurrency and to stay long Apple (NASDAQ:AAPL) through an upcoming leadership change.

24/7 Wall Street • Aug 31, 2026

Best Dividend Aristocrats For September 2026

Dividend Aristocrats, tracked via NOBL, delivered a 12.9% YTD return, closely trailing SPY's 13.68%, with 29 Aristocrats outperforming SPY in 2026. Top 2026 performers include TGT (+73.04%), NUE (+55.64%), and BEN (+49.25%), highlighting strong sectoral momentum among select Aristocrats. Six Aristocrats announced dividend increases in the past month, pushing the group's average 2026 dividend growth rate to 4.30%, up from 4.10% last month.

Seeking Alpha • Aug 28, 2026

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture.

PRNewsWire • Aug 27, 2026

BD to Present at Wells Fargo 21st Annual Healthcare Conference

FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m.

PRNewsWire • Aug 26, 2026

Best Dividend Kings: August 2026

Dividend Kings are outperforming the S&P 500 YTD, with a 14.98% total return versus SPY's 12.89%. Thirty Dividend Kings are beating SPY, and 25 appear both potentially undervalued and offer ≥10% annualized return potential. Dividend growth among Kings accelerated, with the average rate rising to 4.12% and several notable increases announced.

Seeking Alpha • Aug 24, 2026

BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

Zacks Investment Research • Aug 20, 2026

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.

PRNewsWire • Aug 17, 2026

Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.

Seeking Alpha • Aug 13, 2026